Top

Published in:

01-04-2011 | Biological Psychiatry - Short Communication

ECT in a patient with Parkinson’s disease and schizophrenia, with dopamine transporter visualisation using 123I-Ioflupane SPET

Authors: Paloma Fernández-Corcuera, Salvatore Aguilar, Víctor Viçens, Jaume Mora, Ana Benitez, Amparo García-Burillo, Edith Pomarol-Clotet, Peter Mckenna

Published in: Journal of Neural Transmission | Issue 4/2011

Abstract

A 58-year old woman with chronic schizophrenia developed worsening parkinsonian symptoms over the previous 6 years, and was eventually diagnosed as having Parkinson’s disease. Antipsychotics were stopped because they worsened these symptoms. Antiparkinsonian treatment led to a significant increase in delusions and behavioural disorganisation. The patient underwent electroconvulsive-therapy which improved both her psychiatric and motor symptoms. After treatment, 123I-Ioflupane uptake was mildly increased in the left caudate nucleus, but uptake in right caudate nucleus was lower than in a pretreatment scan.

Andersen K, Balldin J, Gottfries CG, Granérus AK, Modigh K, Svennerholm L, Wallin A (1987) A double-blind evaluation of electroconvulsive therapy in Parkinson disease with “on-off” phenomena. Acta Neurol Scand 76(3):191–199PubMedCrossRef

Bruins Slot LA, Palmier C, Tardif S, Cussac D (2007) Actions of novel antipsychotics at human D3 receptors coupled to G protein and ERK1/2 activation. Neuropharmacology 53(2):232–241PubMedCrossRef

Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Murherjee J (2006) D2/D3 dopamine receptor binding with (F-18) fallypride in thalamus and cortex patients with schizophrenia. Schizophr Res 85(1–3):232–244PubMedCrossRef

Fahn S, Elton R (1987) Members of the updrs Development Committee Recent Developments in Parkinson’s Disease. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds). Macmillan Health Care Information, vol 2, pp 153–163, 293–304. Florham Park

Fall PA, Ekman R, Granérus AK, Thorell LH, Wålinder J (1995) ECT in Parkinson’s disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm Park Dis Dement Sect 10(2-3):129–140PubMedCrossRef

Fall PA, Ekberg S, Granérus AK, Granérus G (2000) ECT in Parkinson’s disease-dopamine transporter visualised by 123I-B-CIT SPECT. J Neural Transm 107:997–1008PubMedCrossRef

Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442PubMed

Krystal AD, Coffey CE (1997) Neuropsychiatric considerations in the use of electroconvulsive therapy. J Neuropsychiatry Clin Neurosci 9(2):283–292PubMed

Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O et al (2000) Striatal dopamine transporter binding in neuroleptic naive patients with schizophrenia studied with PET. Am J Psychiatry 157:269–271PubMedCrossRef

Lahti AC, Weiler M, Carlsson A, Tamminga CA (1998) Effects of the D3 and auto receptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm 105(6–7):719–734PubMedCrossRef

Lammers CH, Diaz J, Schwartz JC, Sokoloff P (2000) Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 5(4):378–388PubMedCrossRef

Landau AM, Chakravarty MM, Clark CM, Zis AP, Doudet DJ (2010) Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology 13:1–8CrossRef

Lorenzo i Bosquet C, Cuberas Borros G, Miquel Rodriguez F, Caresia P, Aguade Bruix S, Castell Conesa J (2005) Quantitative evaluation of 123I-FP-CIT SPECT: validation of a semiautomated method. Rev Esp Med Nucl 24(4):244–249CrossRef

Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernández-Egea E, Pavia J, Prats A, Pons F, Bernardo M (2007) Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggest an illness trait. Psychopharmacology (Berl) 191(3):805–811CrossRef

Mehler-Wex C, Riederer P, Gerlach M (2006) Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 3–4:167–179CrossRef

Ortega Lozano SJ, Martínez del Valle Torres MD, Jiménez-Hoyuela García JM, Gutierrez Cardo AL, Campos Arillo V (2007) Diagnostic accuracy of FP-CIT SPECT in patients with parkinsonism. Rev Esp Med Nucl 26(5):277–285PubMedCrossRef

Rizos EN, Chatziioannou S, Douzenis A, Siafakas N, Katsantoni E, Nikolaidou P, Papathanasiou M, Lykouras L (2010a) Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan. Eur Neuropsychopharmacol 20(2):132–136PubMedCrossRef

Rizos EN, Chatziioannou S, Siafakas N, Douzenis A, Katsantoni E, Mandrapilia A, Bacalis S, Fotiadis C, Lykouras L (2010b) Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia—a case report. Prog Neuropsychopharmacol Biol Psychiatry 34(6):1135–1136PubMedCrossRef

Strome EM, Zis AP, Doudet DJ (2007) Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J Psychiatry Neurosci 32(3):193–202PubMed

Tolosa E, Borght TV, Moreno E (2007) DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord 22(16):2346–2351

Vogel M, Pfeifer S, Schaub RT, Grabe HJ, Barnow S, Freyberger HJ, Cascorbi I (2004) Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50(4):305–310PubMedCrossRef

Vogel M, Busse S, Freyberger HJ, Grabe HJ (2006) Dopamine D3 receptor and schizophrenia: a widened scope for the immune hypothesis. Med Hipotheses 67(2):354–358CrossRef

Title: ECT in a patient with Parkinson’s disease and schizophrenia, with dopamine transporter visualisation using 123I-Ioflupane SPET
Authors: Paloma Fernández-Corcuera
Salvatore Aguilar
Víctor Viçens
Jaume Mora
Ana Benitez
Amparo García-Burillo
Edith Pomarol-Clotet
Peter Mckenna
Publication date: 01-04-2011
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 4/2011
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-011-0615-8

At a glance: The STEP trials

Springer Medicine

ECT in a patient with Parkinson’s disease and schizophrenia, with dopamine transporter visualisation using 123I-Ioflupane SPET

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Substantia nigra hyperechogenicity is a risk marker of Parkinson’s disease: yes

Thermal hypesthesia in patients with complex regional pain syndrome related dystonia

Down regulation of trophic factors in neonatal rat spinal cord after administration of cerebrospinal fluid from sporadic amyotrophic lateral sclerosis patients

The extracranial vascular theory of migraine: an artificial controversy

Micrographia induced by pallidal DBS for segmental dystonia: a subtle sign of hypokinesia?

Screening for anorexia nervosa via measurement of serum leptin levels